α-葡萄糖苷酶抑制剂在2型糖尿病早期治疗中的应用
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.
作者信息
van de Laar Floris Alexander
机构信息
Radboud University Nijmegen Medical Centre, Department of General Practice, Nijmegen, The Netherlands.
出版信息
Vasc Health Risk Manag. 2008;4(6):1189-95. doi: 10.2147/vhrm.s3119.
Abstract
Alpha-glucosidase inhibitors (AGIs) are drugs that inhibit the absorption of carbohydrates from the gut and may be used in the treatment of patients with type 2 diabetes or impaired glucose tolerance. There is currently no evidence that AGIs are beneficial to prevent or delay mortality or micro- or macrovascular complications in type 2 diabetes. Its beneficial effects on glycated hemoglobin are comparable to metformin or thiazolidinediones, and probably slightly inferior to sulphonylurea. In view of the total body of evidence metformin seems to be superior to AGIs. More long-term studies are needed to study the effects of AGIs compared to other drugs. For patient with impaired glucose tolerance AGIs may prevent, delay or mask the occurrence of type 2 diabetes. A possible beneficial effect on cardiovascular events should be confirmed in new studies.
摘要
α-葡萄糖苷酶抑制剂（AGIs）是一类抑制碳水化合物在肠道吸收的药物，可用于治疗2型糖尿病患者或糖耐量受损患者。目前尚无证据表明AGIs对预防或延缓2型糖尿病患者的死亡率或微血管或大血管并发症有益。其对糖化血红蛋白的有益作用与二甲双胍或噻唑烷二酮类药物相当，可能略逊于磺脲类药物。鉴于现有证据，二甲双胍似乎优于AGIs。与其他药物相比，需要更多的长期研究来研究AGIs的效果。对于糖耐量受损的患者，AGIs可能预防、延缓或掩盖2型糖尿病的发生。其对心血管事件可能存在的有益作用应在新的研究中得到证实。
相似文献
1
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.α-葡萄糖苷酶抑制剂在2型糖尿病早期治疗中的应用
Vasc Health Risk Manag. 2008;4(6):1189-95. doi: 10.2147/vhrm.s3119.
2
Who should benefit from the use of alpha-glucosidase inhibitors?哪些人应该从使用α-葡萄糖苷酶抑制剂中获益？
Curr Diab Rep. 2007 Oct;7(5):333-9. doi: 10.1007/s11892-007-0055-x.
3
Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.用于糖耐量受损或空腹血糖受损人群的α-葡萄糖苷酶抑制剂。
Cochrane Database Syst Rev. 2006 Oct 18(4):CD005061. doi: 10.1002/14651858.CD005061.pub2.
4
Oral antidiabetic agents: current role in type 2 diabetes mellitus.口服抗糖尿病药物：在2型糖尿病中的当前作用
Drugs. 2005;65(3):385-411. doi: 10.2165/00003495-200565030-00005.
5
Alpha-glucosidase inhibitors for type 2 diabetes mellitus.用于2型糖尿病的α-葡萄糖苷酶抑制剂
Cochrane Database Syst Rev. 2005 Apr 18;2005(2):CD003639. doi: 10.1002/14651858.CD003639.pub2.
6
Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.在治疗 2 型糖尿病时使用 α-葡萄糖苷酶抑制剂的注意事项。
Expert Opin Pharmacother. 2019 Dec;20(18):2229-2235. doi: 10.1080/14656566.2019.1672660. Epub 2019 Oct 8.
7
alpha-Glucosidase inhibitors.α-葡萄糖苷酶抑制剂
Endocrinol Metab Clin North Am. 1997 Sep;26(3):539-51. doi: 10.1016/s0889-8529(05)70266-8.
8
Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.α-葡萄糖苷酶抑制剂在2型糖尿病中的治疗潜力：一项基于证据的综述。
Expert Opin Pharmacother. 2015;16(13):1959-81. doi: 10.1517/14656566.2015.1070827.
9
Can alpha-glucosidase inhibitors reduce the insulin dosage administered to patients with non-insulin-dependent diabetes mellitus?
J Int Med Res. 1995 Nov-Dec;23(6):487-91. doi: 10.1177/030006059502300611.
10
Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance.α-葡萄糖苷酶抑制剂在老年糖尿病及糖耐量受损患者中的应用潜力
Drugs Aging. 1998 Aug;13(2):131-43. doi: 10.2165/00002512-199813020-00005.
引用本文的文献
1
Polyphenolic Profiling and Evaluation of Antioxidant, Antidiabetic, Anti-Alzheimer, and Antiglaucoma Activities of and var. azurea.和天蓝变种的多酚谱分析及其抗氧化、抗糖尿病、抗阿尔茨海默病和抗青光眼活性评估。
Life (Basel). 2025 Jul 29;15(8):1209. doi: 10.3390/life15081209.
2
Lannea edulis lowers blood glucose by modulating absorption, utilization, and pancreatic function in diabetic rats.食用榄仁通过调节糖尿病大鼠的吸收、利用和胰腺功能来降低血糖。
Front Pharmacol. 2025 Aug 1;16:1618241. doi: 10.3389/fphar.2025.1618241. eCollection 2025.
3
Natural solutions for diabetes: the therapeutic potential of plants and mushrooms.糖尿病的天然解决方案：植物和蘑菇的治疗潜力。
Front Nutr. 2025 Jul 4;12:1511049. doi: 10.3389/fnut.2025.1511049. eCollection 2025.
4
Synthesis, structural insights and bio-evaluation of -phenoxyethylisatin hydrazones as potent α-glucosidase inhibitors.作为强效α-葡萄糖苷酶抑制剂的苯氧基乙基异吲哚酮腙的合成、结构见解及生物评价
RSC Adv. 2025 May 7;15(19):14717-14729. doi: 10.1039/d5ra00770d. eCollection 2025 May 6.
5
Exploring the antidiabetic activity of potential probiotic bacteria isolated from traditional fermented beverage.探索从传统发酵饮料中分离出的潜在益生菌的抗糖尿病活性。
World J Microbiol Biotechnol. 2024 Dec 18;41(1):10. doi: 10.1007/s11274-024-04226-1.
6
The Potential Therapeutic Use of Agarwood for Diabetes: A Scoping Review.沉香对糖尿病的潜在治疗用途：一项范围综述
Pharmaceuticals (Basel). 2024 Nov 18;17(11):1548. doi: 10.3390/ph17111548.
7
Pharmacophore-based 3D-QSAR modeling, virtual screening, docking, molecular dynamics and biological evaluation studies for identification of potential inhibitors of alpha-glucosidase.基于药效团的 3D-QSAR 建模、虚拟筛选、对接、分子动力学和生物评价研究，以鉴定潜在的α-葡萄糖苷酶抑制剂。
J Mol Model. 2024 Oct 30;30(11):389. doi: 10.1007/s00894-024-06181-y.
8
Genus: A Promising Source of Compounds with Nutritional and Biological Properties.属：具有营养和生物特性化合物的有前途的来源。
Molecules. 2024 Jun 1;29(11):2612. doi: 10.3390/molecules29112612.
9
Secondary metabolic profiling, antioxidant potential, enzyme inhibitory activities and in silico and ADME studies: a multifunctional approach to reveal medicinal and industrial potential of Tanacetum falconeri.次生代谢产物分析、抗氧化潜力、酶抑制活性及计算机辅助药物设计和药物代谢研究：揭示鹰爪菊的药用和工业潜力的多功能方法。
BMC Complement Med Ther. 2024 Apr 22;24(1):167. doi: 10.1186/s12906-024-04459-5.
10
Discovery of New Dual-Target Agents Against PPAR-γ and α-Glucosidase Enzymes with Molecular Modeling Methods: Molecular Docking, Molecular Dynamic Simulations, and MM/PBSA Analysis.采用分子对接、分子动力学模拟和 MM/PBSA 分析等方法发现新型双重靶向 PPAR-γ 和α-葡萄糖苷酶的药物。
Protein J. 2024 Jun;43(3):577-591. doi: 10.1007/s10930-024-10196-y. Epub 2024 Apr 20.
本文引用的文献
1
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.罗格列酮对心肌梗死风险及心血管原因所致死亡的影响。
N Engl J Med. 2007 Jun 14;356(24):2457-71. doi: 10.1056/NEJMoa072761. Epub 2007 May 21.
2
Low-dose acarbose does not delay digestion of starch but reduces its bioavailability.低剂量阿卡波糖不会延迟淀粉的消化，但会降低其生物利用度。
Diabet Med. 2007 Jun;24(6):600-6. doi: 10.1111/j.1464-5491.2007.02115.x. Epub 2007 Mar 22.
3
Impaired fasting glucose and impaired glucose tolerance: implications for care.空腹血糖受损和糖耐量受损：对治疗的启示
Diabetes Care. 2007 Mar;30(3):753-9. doi: 10.2337/dc07-9920.
4
Medicalisation in the 21st century: introduction.21世纪的医学化：引言
Lancet. 2007 Feb 24;369(9562):697-8. doi: 10.1016/S0140-6736(07)60317-1.
5
Finding new treatments for diabetes--how many, how fast... how good?寻找糖尿病的新疗法——数量多少、速度多快……效果多好？
N Engl J Med. 2007 Feb 1;356(5):437-40. doi: 10.1056/NEJMp068294.
6
Diagnosis and classification of diabetes mellitus.糖尿病的诊断与分类
Diabetes Care. 2007 Jan;30 Suppl 1:S42-7. doi: 10.2337/dc07-S042.
7
Pioglitazone for type 2 diabetes mellitus.吡格列酮用于2型糖尿病
Cochrane Database Syst Rev. 2006 Oct 18;2006(4):CD006060. doi: 10.1002/14651858.CD006060.pub2.
8
Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.用于糖耐量受损或空腹血糖受损人群的α-葡萄糖苷酶抑制剂。
Cochrane Database Syst Rev. 2006 Oct 18(4):CD005061. doi: 10.1002/14651858.CD005061.pub2.
9
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.罗格列酮对糖耐量受损或空腹血糖受损患者糖尿病发生频率的影响：一项随机对照试验。
Lancet. 2006 Sep 23;368(9541):1096-105. doi: 10.1016/S0140-6736(06)69420-8.
10
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.2型糖尿病高血糖管理：治疗起始与调整的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明
Diabetes Care. 2006 Aug;29(8):1963-72. doi: 10.2337/dc06-9912.
Zotero 插件